CAL-51 Cells
CAD$579.60*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | The CAL-51 cell line is a human breast adenocarcinoma model established from a malignant pleural effusion of a patient with advanced breast cancer. Characterized by epithelial morphology and a normal diploid karyotype, CAL-51 is particularly notable for its triple-negative breast cancer (TNBC) profile, lacking estrogen receptor (ER), progesterone receptor (PR), and HER2 expression. The absence of these markers, commonly used as therapeutic targets, makes CAL-51 a valuable model for studying TNBC, an aggressive subtype of breast cancer with limited treatment options. CAL-51’s tumorigenicity in immunocompromised mice and growth in soft agar demonstrate its malignant potential, making it suitable for in vitro and in vivo cancer research. CAL-51 has also shown utility in studies investigating SARS-CoV-2 infection mechanisms. High expression of cellular entry factors ACE2 and TMPRSS2, along with neuropilin-1 (NRP1), renders CAL-51 permissive to SARS-CoV-2, facilitating viral entry and replication in cell culture. This makes CAL-51 a suitable model for exploring viral pathogenesis, as well as testing antiviral compounds and neutralizing antibodies targeted at SARS-CoV-2. Experiments demonstrate that therapeutic antibodies can block SARS-CoV-2 entry effectively in CAL-51 cells, highlighting its relevance as a model system for COVID-19 research and potential therapeutic evaluation. In cancer research, CAL-51 is particularly useful for examining tumor heterogeneity, especially through its subpopulations of stem-like cancer cells known as side populations (SP), which express high levels of the ABCG2 transporter. SP cells in CAL-51 exhibit enhanced drug resistance and potential self-renewal, characteristics relevant to studies on cancer stem cell behavior and treatment resistance. As such, CAL-51 is a versatile model contributing to both cancer and viral infection studies, supporting research into challenging therapeutic areas such as TNBC and SARS-CoV-2. |
|---|---|
| Organism | Human |
| Tissue | Breast |
| Disease | Carcinoma |
| Metastatic site | Pleural effusion |
| Synonyms | CAL 51, CAL51, Cal51, Centre Antoine Lacassagne-51 |
Characteristics
| Age | 45 years |
|---|---|
| Gender | Female |
| Ethnicity | Caucasian |
| Morphology | Epithelial-like |
| Growth properties | Monolayer, adherent |
Regulatory Data
| Citation | CAL-51 (Cytion catalog number 305530) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_1110 |
Biomolecular Data
Handling
| Culture Medium | DMEM, w: 4.5 g/L Glucose, w: 4 mM L-Glutamine, w: 3.7 g/L NaHCO3, w: 1.0 mM Sodium pyruvate (Cytion article number 820300a) |
|---|---|
| Supplements | Supplement the medium with 10% FBS |
| Dissociation Reagent | Accutase |
| Subculturing | Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium. |
| Seeding density | 1.25 x 104 cells/cm2 |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 305530-081225 | Certificate of Analysis | 22. Jan. 2026 | 305530 |